Filing Flows › Puma Biotechnology (PBYI) › Q2 2025
Puma Biotechnology (PBYI) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Puma Biotechnology (PBYI) reported revenue of $52.4M for the second quarter 2025 (Q2 2025), +11% from a year earlier and +14% from the quarter before. Operating margin was 12.7%, net earnings $5.9M (11.2% of revenue).
Puma Biotechnology, Q2 2025: revenue $52.4M (+11% year over year), operating margin 12.7%, net earnings $5.9M, operating cash flow $14.1M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $52.4M | +14% | +11% |
| Operating profit | $6.6M | +67% | — |
| Net earnings | $5.9M | +97% | — |
| Operating cash flow | $14.1M | +290% | 14× |
| Free cash flow | $14.1M | +296% | 14× |
What changed
Revenue was $52.4M in Q2 2025, up 11% year over year and up 14% from the previous quarter. Product was the largest line at 94% of revenue. Product added $4.8M year over year (up 11%), 90% of the total change.
Operating profit was $6.6M, a 12.7% margin (up 17.3 points year over year). Total costs fell 7% while revenue rose 11%. The fastest-growing cost line was Cost of revenue (+15%). Net earnings were $5.9M. The effective tax rate was 5.0%.
Operating cash flow was $14.1M (up 1271% year over year), 241% of net earnings. Non-cash charges added back $2.8M of depreciation and amortization and $1.6M of share-based compensation. Working capital and other items added $3.8M. Capital expenditures of $20K left free cash flow of $14.1M.
Questions
What was Puma Biotechnology's revenue in the second quarter 2025?
Puma Biotechnology (PBYI) reported revenue of $52.4M for the second quarter 2025 (Q2 2025), +11% from a year earlier and +14% from the quarter before.
Was Puma Biotechnology profitable in the second quarter 2025?
Operating profit was $6.6M (12.7% of revenue) and net earnings $5.9M.
Source: Puma Biotechnology 10-Q on SEC EDGAR.